Scarica l'app Stockscreener
2.24
6.67%
-0.16
Dopo l'orario di chiusura:
2.24
Acumen Pharmaceuticals Inc Borsa (ABOS) Ultime notizie
HC Wainwright Has Pessimistic View of ABOS FY2024 Earnings - MarketBeat
Analyzing Ginkgo Bioworks (NYSE:DNA) & Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Up 14.2% in October - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Given Buy Rating at HC Wainwright - MarketBeat
Earnings call: Acumen Pharmaceuticals reports on Q3 2024 progress - Investing.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2024 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals Advances Alzheimer’s Therapeutic - TipRanks
Acumen Pharmaceuticals' Shares Drop on Wider 3Q Loss - MarketWatch
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Acumen Reports $258.9M Cash Runway Despite Widening Q3 Loss; Alzheimer's Trial Advances | ABOS Stock News - StockTitan
Earnings Scheduled For November 12, 2024 - Benzinga
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference - The Manila Times
Acumen Pharma to Present Alzheimer's Treatment Progress at Stifel Healthcare Conference | ABOS Stock News - StockTitan
Acumen Pharma announces new appointment | Biotechnology | The Pharmaletter - The Pharma Letter
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference - The Manila Times
Acumen Pharma to Present Alzheimer's Treatment Progress at UBS Healthcare Conference | ABOS Stock News - StockTitan
Acumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on Tuesday - MarketBeat
Acumen Pharmaceuticals appoints new regulatory chief - Investing.com
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality - The Manila Times
Acumen Pharma Taps Former Sage Executive to Lead Alzheimer's Drug Development | ABOS Stock News - StockTitan
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - WICZ
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference - The Manila Times
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference - StockTitan
Uipath Inc Cl A (PATH-N) QuotePress Release - The Globe and Mail
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Decrease in Short Interest - MarketBeat
National Bank Financial Forecasts TSE:BIP Q3 Earnings - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 18.6% in October - Defense World
Acumen reveals Alzheimer's trial screening method By Investing.com - Investing.com Australia
Halozyme to Report Third Quarter 2024 Financial and Operating Results - The Malaysian Reserve
Acumen reveals Alzheimer's trial screening method - Investing.com India
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on - The Bakersfield Californian
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
3 US Penny Stocks With Market Caps Under $500M To Consider - Simply Wall St
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Decreases By 7.7% - MarketBeat
Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Millennium Management LLC Has $4.87 Million Position in Exponent, Inc. (NASDAQ:EXPO) - Defense World
Millennium Management LLC Makes New Investment in Super Hi International Holding Ltd. (NASDAQ:HDL) - Defense World
Millennium Management LLC Has $4.88 Million Stock Position in Alamo Group Inc. (NYSE:ALG) - Defense World
Millennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - MarketBeat
Central Nervous System (CNS) Biomarkers Market Expected - openPR
Renaissance Technologies LLC Acquires Shares of 338,100 Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - MarketBeat
Acumen Pharmaceuticals (ABOS) Price Target Increased by 6.67% to 13.06 - MSN
MGO Private Wealth LLC Buys 9,590 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Sei Investments Co. Makes New $2.49 Million Investment in Plains GP Holdings, L.P. (NYSE:PAGP) - Defense World
Stifel maintains Buy rating on Acumen Pharma shares - Investing.com India
Park National Corp OH Boosts Stake in Vanguard High Dividend Yield ETF (NYSEARCA:VYM) - Defense World
Acumen Pharma retains stock target with Buy rating on AD drug potential - Investing.com India
Analysts’ Updated EPS Estimates for October 3rd (ABOS, AIOT, AMZN, ATLX, BCTX, BIGC, BITF, BTDR, CAG, CALX) - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Given "Buy" Rating at HC Wainwright - MarketBeat
Acumen Pharma retains stock target with Buy rating on AD drug potential By Investing.com - Investing.com South Africa
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):